Barclays Maintains Overweight on First Tracks, Raises Price Target to $65
Barclays analyst Etzer Darout maintains First Tracks (NASDAQ:TRAX) with a Overweight and raises the price target from $48 to $65.
Read original at benzingaStocks · News reference
First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results
TRAX reported narrower Q2 loss of 95 cents per share. Analysts raised price targets for the stock, citing potential for ANB033 in immune diseases.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 1:07 PM
- Checked
- Aug 13, 2026, 1:07 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Wedbush Maintains Outperform on First Tracks, Raises Price Target to $70
Wedbush analyst Martin Fan maintains First Tracks (NASDAQ:TRAX) with a Outperform and raises the price target from $60 to $70.
Read original at benzingaPiper Sandler Maintains Overweight on First Tracks, Raises Price Target to $95
Piper Sandler analyst Yasmeen Rahimi maintains First Tracks (NASDAQ:TRAX) with a Overweight and raises the price target from $54 to $95.
Read original at benzinga